Capricorn Venture Partners, a pan-European manager of venture capital funds seeking to invest in technology based growth companies, launched the €120m Capricorn Health-tech Fund (CHF).
The human health-technology sector comprises a diverse range of products and services including biopharmaceutical and pharmaceutical drugs, vaccines, medical devices, medical imaging, diagnostics, nutraceuticals and functional foods. The fund will invest in European early to mid stage companies whose business and products relate to the prevention, the diagnosis or the treatment of diseases.
Leuven, Belgium-based Capricorn Venture Partners is currently investing out of its €112m Capricorn Cleantech Fund. This fund invests in European growth companies developing innovative breakthrough technologies in the fields of renewable energy and energy efficiency, water purification and re-use, bio based material conversion and biorefinery platforms, clean air, climate change, green chemistry and advanced materials, materials recovery and recycling.
The investment team of Capricorn is composed of experienced investment managers with deep technology expertise and a broad industrial experience.
In preparation of raising and managing the new fund, the firm has expanded its senior team with:
– Dr Frank Bulens,
– Ir Els Hubloux,
– Dr Els Vanheusden.
The investment activity will start following the first closing of the new fund, which is planned to take place at € 30m.